These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37834066)

  • 1.
    Zhou Y; Bi Z; Hamilton MJ; Zhang L; Su R; Sadowsky MJ; Roy S; Khoruts A; Chen C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.
    Xu Q; Zhang S; Quan J; Wu Z; Gu S; Chen Y; Zheng B; Lv L; Li L
    Appl Microbiol Biotechnol; 2022 Oct; 106(19-20):6689-6700. PubMed ID: 36085529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent
    Mullish BH; McDonald JAK; Pechlivanis A; Allegretti JR; Kao D; Barker GF; Kapila D; Petrof EO; Joyce SA; Gahan CGM; Glegola-Madejska I; Williams HRT; Holmes E; Clarke TB; Thursz MR; Marchesi JR
    Gut; 2019 Oct; 68(10):1791-1800. PubMed ID: 30816855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.
    Monaghan T; Mullish BH; Patterson J; Wong GK; Marchesi JR; Xu H; Jilani T; Kao D
    Gut Microbes; 2019; 10(2):142-148. PubMed ID: 30183484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection.
    Lee PC; Chang TE; Wang YP; Lee KC; Lin YT; Chiou JJ; Huang CW; Yang UC; Li FY; Huang HC; Wu CY; Huang YH; Hou MC
    J Formos Med Assoc; 2022 Sep; 121(9):1636-1646. PubMed ID: 34836663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
    Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
    mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
    Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
    Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal microbiota transplantation for treatment of patients with recurrent
    Voth E; Khanna S
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent
    Wei S; Bahl MI; Baunwall SMD; Dahlerup JF; Hvas CL; Licht TR
    Gut Microbes; 2022; 14(1):2084306. PubMed ID: 36519447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome.
    Gotoh K; Sakaguchi Y; Kato H; Osaki H; Jodai Y; Wakuda M; Také A; Hayashi S; Morita E; Sugie T; Ito Y; Ohmiya N
    Anaerobe; 2022 Feb; 73():102502. PubMed ID: 34896553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
    Vaughn BP; Fischer M; Kelly CR; Allegretti JR; Graiziger C; Thomas J; McClure E; Kabage AJ; Khoruts A
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1330-1337.e2. PubMed ID: 36126907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
    Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
    Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.
    Weingarden AR; Chen C; Bobr A; Yao D; Lu Y; Nelson VM; Sadowsky MJ; Khoruts A
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G310-9. PubMed ID: 24284963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
    Hui W; Li T; Liu W; Zhou C; Gao F
    PLoS One; 2019; 14(1):e0210016. PubMed ID: 30673716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
    Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
    Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Landscape of Fecal Microbial Transplantation.
    Shao T; Hsu R; Hacein-Bey C; Zhang W; Gao L; Kurth MJ; Zhao H; Shuai Z; Leung PSC
    Clin Rev Allergy Immunol; 2023 Oct; 65(2):101-120. PubMed ID: 36757537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study.
    Baunwall SMD; Hansen MM; Andreasen SE; Eriksen MK; Rågård N; Kelsen J; Grosen AK; Mikkelsen S; Erikstrup C; Dahlerup JF; Hvas CL
    Aliment Pharmacol Ther; 2023 Sep; 58(5):503-515. PubMed ID: 37482926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
    Bernard R; Hourigan SK; Nicholson MR
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S58-S63. PubMed ID: 34791396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.